All In Biotech

Drug Trial Radar · NCT05514054

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

8,000

Planned (sponsor's estimate)

Start

Oct 4, 2022

Primary completion

Oct 2027

Study completion Mar 2032

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.

Conditions

  • Breast Neoplasms

Interventions

  • ImlunestrantDrug

    Administered orally.

  • TamoxifenDrug

    Administered per local approved label.

  • AnastrozoleDrug

    Administered per local approved label.

  • LetrozoleDrug

    Administered per local approved label.

  • ExemestaneDrug

    Administered per local approved label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS)Time frame: Randomization to recurrence or death from any cause (up to 10 years)

Locations

672 sites in 31 countries. Site status is shown where the registry gives one.

  • USO - Southern Cancer Center

    Daphne, Alabama

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Infirmary Cancer Care

    Mobile, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • USO - Arizona Oncology Associates - HAL

    Glendale, Arizona

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona

  • TMC HealthCare

    Tucson, Arizona

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • UCSF - John Muir Health Cancer Center Berkeley

    Berkeley, California

  • Washington Health

    Fremont, California

  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine

    Irvine, California

  • Loma Linda University Cancer Center

    Loma Linda, California

  • Pacific Cancer Care

    Monterey, California

  • St. Joseph Hospital

    Orange, California

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente San Diego Mission Road

    San Diego, California

  • Zuckerberg San Francisco General Hospital and Trauma Center

    San Francisco, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Saint Joseph's Medical Center

    Stockton, California

  • Anschutz Cancer Pavilion

    Aurora, Colorado

  • UCHealth Memorial Hospital

    Colorado Springs, Colorado

  • UCHealth Harmony

    Fort Collins, Colorado

  • Banner MD Anderson Cancer Center at North Colorado Medical Center

    Greeley, Colorado

  • USO - Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Banner MD Anderson Cancer Center at McKee Medical Center

    Loveland, Colorado

  • Yale-New Haven Hospital

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • AdventHealth Altamonte Springs

    Altamonte Springs, Florida

  • Memorial Regional Hospital

    Hollywood, Florida

  • Millennium Oncology Research Clinic

    Hollywood, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • USO - Cancer Care Centers of Brevard

    Palm Bay, Florida

  • USO - Woodlands Medical Specialists

    Pensacola, Florida

  • Miami Cancer Institute - Plantation

    Plantation, Florida

  • Tampa General Hospital

    Tampa, Florida

Showing 40 of 672 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.